Diffuse Large B-cell Lymphoma Prognosis Calculator
Estimate survival outcomes using the revised International Prognostic Index (IPI) score
Calculate DLBCL Prognosis
Prognosis Results
Very good prognosis
Excellent prognosis with very high survival rates
⚠️ Medical Disclaimer: This calculator provides prognostic estimates based on statistical models. Individual patient outcomes may vary significantly. Always consult with qualified hematology/oncology specialists for comprehensive evaluation, treatment planning, and prognosis assessment. These results are for educational purposes only and should not replace professional medical judgment.
Clinical Interpretation
• Excellent prognosis - Standard R-CHOP chemotherapy typically sufficient
• Regular staging and response assessment recommended
• CNS prophylaxis may be indicated in high-risk patients
Example Patient Assessment
Patient Case Example
Patient: 65-year-old with newly diagnosed DLBCL
Stage: IV (multiple nodal regions + liver involvement)
LDH: 450 U/L (elevated)
Performance Status: ECOG 1 (ambulatory, restricted)
Extranodal sites: 2 (liver and bone marrow)
IPI Score Calculation
Age >60 years: +1 point
Stage III-IV: +1 point
Elevated LDH: +1 point
ECOG 0-1: 0 points
Multiple extranodal sites: +1 point
Total IPI Score: 4 points = Poor prognosis
IPI Risk Groups
Very Good
4-year OS: 94%
No risk factors
Good
4-year OS: 84%
One risk factor
Intermediate
4-year OS: 66%
Two risk factors
Poor
4-year OS: 54%
3+ risk factors
DLBCL Facts
Most common non-Hodgkin lymphoma (~30%)
Aggressive B-cell lymphoma
Median age: 70 years
Rapidly growing tumor mass
Can be cured with intensive chemotherapy
Understanding DLBCL and IPI Scoring
What is DLBCL?
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of all cases. It's an aggressive cancer that develops from B-cells (white blood cells) and can quickly spread throughout the body.
Common Symptoms
- •Rapidly enlarging lymph nodes
- •Fever, night sweats, weight loss (B-symptoms)
- •Fatigue and weakness
- •Abdominal pain or swelling
IPI Scoring System
The International Prognostic Index (IPI) is a clinical prediction tool used to estimate outcomes in patients with aggressive lymphomas like DLBCL. It considers five key risk factors:
- Age: >60 years (adverse factor)
- Stage: III-IV vs I-II (advanced vs limited)
- LDH: Elevated vs normal (tumor burden marker)
- Performance Status: ECOG 2-4 vs 0-1 (functional status)
- Extranodal sites: >1 vs 0-1 (extent of spread)
Note: The age-adjusted IPI excludes age factor and is used for patients <60 years old
Treatment Implications
Very Good/Good Prognosis (0-1 points)
- • Standard R-CHOP chemotherapy
- • 6-8 cycles typically sufficient
- • Excellent cure rates expected
- • Close monitoring during treatment
Intermediate/Poor Prognosis (2+ points)
- • Consider dose-dense regimens (R-CHOP-14)
- • Clinical trial participation
- • CNS prophylaxis evaluation
- • Autologous stem cell transplant consideration